Given the relationship between CysLT and angiotensin II, along with the fact that treatment with RAAS inhibitors was interrupted during hospitalization in ICU patients, we could hypothesize that the maintenance, whenever possible, of antihypertensive treatment with RAAS inhibitors might be potentially beneficial for critical COVID-19 patients on VV-ECMO. The gene discussed is AGT; the disease is COVID-19.